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Prevention by Nifedipine of Cold Pressor-Induced Decrease in Left
Ventricular Ejection Fraction
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B. LEONARD HOLMAN , MD, FACC , RICHARD W. NESTa, MD,
GILBERT H. MUDGE, Jr., MD, FACC, JAMES E. MULLER , MD, FACC,
JOSEPH KOZLOWSKI, RT, JOSHUA WYNNE, MD, FACC
Boston. Massachusetts
To examine the effects of nifedipine on changes in ven-
tricular function produced by cold, the cold pressor test
was administered to eight patients with angiographically
documented coronary artery disease. Radionuclide ven-
triculograms were obtained at baseline and during the
cold pressor stimulus both before and after administra-
tion ofnifedipine, 10 mg buccally; thus, four serial radio-
nuclide ventriculograms were obtained per patient.
The cold pressor stimulus did not produce any sig-
nificant difference in the mean ( ± standard deviation)
peak rate-pressure product during the control or nifed-
ipine test (10,900 ± 3,390 versus 10,600 ± 3,700).
However, the increase in systolic blood pressure (p =
0.05) and the peak systolic blood pressure achieved (p
< 0.001) were greater during the control (134 ± 19 to
160 ± 25 mm Hg) than during the nifedipine (125 ±
18 to 145 ± 21 mm Hg) cold pressor test. The mean
Myocardial ischemia may result from abnormal coronary
artery vasoreactivity (I) as well as from fixed obstructive
lesions of the coronary arteries. Coronary artery vasospasm
has been well documented as the cause of Prinzrnetal 's
variant ang ina (2- 4), but it has not been considered an
important cause of stable exe rtional ang ina. However, there
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global left ventricular ejection fraction decreased during
the control cold pressor test from a baseline value of
0.60 ± 0.08 to 0.52 ± 0.08 (p =0.004). After nifedipine,
this variable did not change during the repeat cold pres-
sor test (0.63 ± 0.09) compared with the repeat baseline
value (0.63 ± 0.11). Therefore, the difference in left
ventricular ejectionfraction responseduring control versus
nifedipine cold pressor testing was highly significant (p
< 0.0001).
In patients with obstructive coronary artery disease,
nifedipine abolished the decrease in left ventricular ejec-
tion fraction observed during the control cold pressor
test and may be of value to protect patients from cold-
induced left ventricular dysfunction. The mechanism may
be a combination of coronary artery vasodilation and
systolic unloading of the left ventricle.
is evidence that vasoconstrictor mechanisms may contribute
to myocardial ischemia in patients with obstructive coronary
artery disease (5 ,6). Nifedipine, a calc ium channel blocking
agent and potent coronary vasodilator, has been used with
increasing frequency to treat angina pectoris associat ed with
obstruct ive coronary artery disease .
In an earlier study at this institution (7) , the hemodynami c
and myocardial metabolic responses to the cold pressor test
before and after admini stration of nifedipine were investi-
gated in patient s with angio graphically documented obstruc-
tive coron ary artery disease. During the control cold pressor
test , mean coronary vascular resistance ( ± standard devia-
tion) increased 18 ± 6%, coronary sinus blood flow was
unchanged and the arterial-coronary sinus oxygen difference
widened from 11.5 ::!:: 1.2 to 12.3 ::!:: 1.2 mll\OO ml. After
admini stration of nifedipine , 10 mg buccally, coronary vas-
cular responses to a repeat cold pressor test were normal .
Mean coronary sinus blood flow increased 27 ± 12%, com-
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nary vascular resistance decreased 10 ± 6% and the arterial-
coronary sinus oxygen difference was unchanged. However,
the effect of nifedipine on cold pressor-induced changes in
left ventricular ejection fraction was not evaluated. Ac-
cordingly, we utilized radionuclide ventriculography to as-
sess serial changes in global left ventricular ejection fraction
during cold pressor tests before and after administration of
nifedipine.
Methods
Patient selection. Patients less than 75 years of age were
considered potential subjects if they had a chest pain syn-
drome consistent with typical stable angina pectoris or a
prior documented myocardial infarction, or both. All po-
tential candidates underwent routine cardiac catheterization
and coronary angiography, which was performed for clinical
indications, at the Brigham and Women's Hospital. Patients
with a 50% or greater left main coronary artery stenosis or
its equivalent were excluded, as were patients with a left
ventricular end-diastolic pressure greater than 18 mm Hg
or a left ventricular ejection fraction less than 0.45. Eight
patients with documented coronary artery disease were se-
lected for study (Table I). All patients completed control
and nifedipine cold pressor tests without developing chest
discomfort, arrhythmias or ischemic electrocardiographic
changes. Clinical and catheterization data are summarized
in Table 1. The mean age (± standard deviation) of the
patients was 46 ± 7 years (range 38 to 60). Six of the eight
patients had prior myocardial infarction. Four patients had
three vessel coronary artery disease, two patients had two
vessel disease and two patients had an isolated stenosis of
the right coronary artery.
Study design. The study protocol was approved by our
institution's Committee for the Protection of Human Sub-
jects. After informed written consent was obtained, calcium
channel blocking agents were discontinued on the evening
before the study; all other medications were continued. On
the following morning, each patient underwent a baseline
radionuclide ventriculogram and 12 lead electrocardiogram.
A 3.0 to 3.4 minute control cold pressor test was then
administered by immersing the patient's left hand in ice
water up to the level of the styloid process. Serial 12 lead
electrocardiograms were obtained every minute during the
cold pressor test, and three electrocardiographic leads (II,
VI and V5) were monitored continuously during the test.
Heart rate was determined from the electrocardiogram. Blood
pressure was determined by indirect sphygmomanometry at
baseline and at every minute during the cold pressor test.
One minute after the start of the cold pressor test, a repeat
radionuclide ventriculogram was initiated and continued un-
til 107 counts were obtained (range 2.0 to 2.4 minutes).
Three to 5 minutes later, nifedipine, 10 mg buccally, was
administered; this dose was chosen because it was used
previously by Gunther et al. (7). The baseline radionuclide
ventriculogram was repeated 20 to 30 minutes after termi-
nation of the control cold pressor test. Immediately after
the second baseline study, the second cold pressor test was
performed.
Radionuclide data acquisition. Gated radionuclide
ventriculograms were obtained utilizing an Anger camera
with a high sensitivity 30° slant hole straight bore collimator
(Engineering Dynamics Corporation) (8). The camera was
interfaced with a dedicated computer system (PDP 11/34,
Digital Equipment Corporation). The technique of data ac-
quisition has been described in detail previously (9). Ba-
sically, it involved the in vivo labeling of red blood cells
by the antecubital intravenous injection of unlabeled stan-
nous pyrophosphate (5 mg of pyrolite), followed by the
injection of 25 mCi of technetium-99m as pertechnetate 15
to 20 minutes later. Five minutes after injection of the radio-
nuclide, the camera was positioned in a modified left anterior
oblique projection using a 30° caudal tilt and sufficient ob-
liquity to separate the right and left ventricles (30 to 40°).
Five minutes after the radionuclide had equilibrated with
the intravascular space, 10 million counts were acquired in
matrix mode in 25 ms frames using commercially available
software (Gamma 11). Only those counts falling within a
15% window centered on the photopeak of technetium-99m
were recorded.
Radionuclide data analysis. An automated computer
algorithm, previously described (8,9), was used to define
background correction regions and to position them relative
to the left ventricular perimeter, which was manually traced
with an electronic cursor. Ejection fraction was calculated
for the entire left ventricle. During the cold pressor tests, a
decrease of more than 0.05 in ejection fraction was defined
as a left ventricular wall motion abnormality. This method
of determining ejection fraction is largely independent of
geometric constraints, and is in close agreement with similar
determinations made using the contrast ventriculogram (9).
Although absolute cardiac volumes were not determined.
relative volume changes were calculated. End-diastolic vol-
ume counts from the left ventricular region of interest were
divided into the total first frame counts to obtain an end-
diastolic volume index which was multiplied by the radio-
nuclide ejection fraction to obtain the stroke volume index.
The stroke volume index was subtracted from the end-di-
astolic volume index to obtain the end-systolic volume in-
dex. The percent changes in end-diastolic and end-systolic
volumes were calculated from baseline to initial cold pressor
test, from the baseline after nifedipine to the repeat cold
pressor test and from initial baseline test to the repeat base-
line study after nifedipine.
Statistical analysis. Each patient served as his own con-
trol. A paired t test was used to test the major null hypothesis
of the study: that there was no significant difference in the
changes in global left ventricular ejection fraction in the
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Table 1. Clmical and Catheterization Data
Medication (mg/day)>
Age Calcium
(yr) Site of Beta-Receptor Long-Acting Channel Blocking
&Sex Prior MI Blocking Drug Nitrate Drug
38M Inf Metoprolol, 100
































(0/( stenosis at angiography)
70% mid LAD;
60% LCx 2nd marginal;
40% mid RCA













90% 1st LAD diagonal;
900/( 2nd LAD diagonal,
7OC;lc l st LCx marginal;
1000/e proximal RCA
40% LAD after Ist septal;
50% Ist LAD diagonal:
50% 3rd LCx large
marginal;
500/e 4th LCx large
marginal;
100% proximal RCA
*No patient was taking digitalis.
Ant-sept = anteroseptal: Inf = inferior; Inf-post = inferoposterior; ISDN = isosorbide dirutrate; LAD =left antenor descending coronary artery; LCx =left
circumflex coronary artery, M = male; MI = myocardial infarction; PDA = posterior descending coronary artery; RCA = right coronary artery.
control cold pressor test compared with baseline ejection
fraction versus ejection fraction in the nifedipine cold pres-
sor test compared with the repeat baseline ejection fraction.
Three minor null hypotheses were also tested: that there was
no significant difference between baseline versus cold pres-
sor left ventricular ejection fraction before and after nifed-
ipine, and that baseline left ventricular ejection fraction
did not differ before and after nifedipine. Because a total
of four paired comparisons were of interest, Bonferroni's
correction for multiple two-way comparisons was used in
which a significant probability (p) value was defined as 0.05/
4 = 0.0125. Therefore, the null hypothesis was rejected
when p < 0.0125. To compare relative radionuclide volume
changes under three conditions-baseline versus control cold
pressor test, repeat baseline versus cold pressor test after
nifedipine and initial versus repeat baseline radionuclide
ventriculogram-a one-way analysis of variance was per-
formed. The data were analyzed using Minitab software (10)
on a Vax 111780 (Digital Equipment Corporation) at Har-
vard University's Health Sciences Computing Facility. Data
are reported as mean ± standard deviation.
Results
Ejection Fraction (Fig. 1)
The control cold pressor stimulus caused a mean increase
in heart rate (beats/min) from 65 ± 14 to 67 ± 11 and an
increase in systolic blood pressure (mm Hg) from 134 ±
19 to 160 ± 25 (Table 2). The global left ventricular ejection
fraction, as assessed by radionuclide ventriculography, de-
creased in seven of the eight patients during the control cold
pressor test. The mean decrease in all patients was from
0.60 ± 0.08 at baseline to 0.52 ± 0.08 after the control
cold pressor test (p = 0.004).
During the nifedipine cold pressor test, the left ventric-
ular ejection fraction did not change compared with the
nifedipine baseline value. The mean ejection fraction was
0.63 ± 0.11 during the nifedipine baseline study versus
0.63 ± 0.09 during the nifedipine cold pressor test.
When the cold pressor test results were compared, the
difference in the change from baseline ventricular ejection
fraction during the control cold pressor test versus change
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Table 2. Heart Rate and Systolic Blood Pressure Changes During Control and Nifedipine Cold Pressor Tests
Heart Rate (beats/min) Blood Pressure (mm Hg) Heart Rate-Systolic Blood Pressure Product
Case Basehne CPT N N + CPT Baseline CPT N N + CPT Baseline CPT N N + CPT
1 71 64 65 71 121/83 130/100 114/90 122/90 8,591 8,320 7,410 8,662
2 54 61 55 61 122/80 166/96 115/80 150192 6,588 10,126 6,325 9,150
3 56 59 54 61 135/80 156/96 126176 152/92 7,560 9,204 6,804 9,272
4 60 67 67 65 152/90 1901112 140/90 160/98 9,120 12,730 9,380 10,400
5 94 91 97 103 170/95 196/120 160/- 180/120 15,980 17,836 15,520 18,540
6 53 55 55 56 114170 140/84 110/80 134/82 6,042 7,700 6,050 7,504
7 61 64 66 68 120/88 134/92 104172 114172 7,320 8,576 6,864 7,752
8 69 75 71 89 140/90 1701104 132192 150/102 9,660 12,750 9,372 13,350
Mean 65 67 66 72 134/84 1601100 125/83 145/94 8,858 10.905 8,466 10.579
±SD 14 II 14 16 19/8 25/11 18/8 21/14 3,131 3,394 3,123 3,703
CPT = cold pressor test; N = nifedipine; SD = standard devianon.
0.9
Heart Rate and Blood Pressure (Table 2)
After nifedipine, the repeat cold pressor stimulus caused
a mean increase in heart rate from 66 ± 14 to 72 ± 16
(beats/min) and an increase in systolic blood pressure from
125 ± 18 to 145 ± 21 mm Hg. During both cold pressor
tests, the increases in mean heart rate and rate-pressure
product did not differ significantly (p = 0.27 and 0.89,
respectively). However, the increases in systolic blood pres-
sure and peak systolic blood pressure were greater during
the control cold pressor test (134 ± 19 to 160 ± 25 mm
Hg) than during the nifedipine cold pressor test (125 ± 28
to 145 ± 21 mm Hg), The difference in the. increase in
systolic blood pressure did not achieve statistical signifi-
cance (p = 0.05), but the difference in peak systolic blood
pressure was highly significant (p < 0.0001).
Discussion
This study demonstrates that the transient abnormal de-
crease in global left ventricular ejection fraction that is pro-
voked by the cold pressor test in patients with coronary
artery disease can be prevented by the administration of
Ventricular Volumes
The percent change in end-diastolic volume did not differ
significantly from the initial baseline to the control cold
pressor test (- 1.3 ± 3.8%), from the repeat baseline to
the cold pressor test after nifedipine (1.8 ± 4.6%), or from
the initial to the repeat baseline radionuclide ventriculogram
(-2.9 ± 6.2%). However, the end-systolic volume in-
creased significantly during the initial cold pressor test (22
± 22%) (p < 0.005), and this increase was blunted during
the cold pressor test after nifedipine (6.9 ± 17%) (p <
0.005). When the initial baseline end-systolic volume was
compared with the repeat baseline end-systolic volume after
nifedipine, the latter showed a significant decrease ( - 13




















Figure 1. Change inglobal leftventricular ejection fraction (LVEF),
as assessed by radionuclide ventriculography (RVG), from the
baselineto the control cold pressor test (CPT) and from the repeat
baseline (post-nifedipine) to nifedipine cold pressor test. NS =:
not significant; p =: probability; SD =: standard deviation; x =:
mean.
-.
from nifedipine baseline during the nifedipine cold pressor
test was highly significant (p < 0.0001). However, the
change in baseline ejection fraction before and after nifed-
ipine (0.60 ± O.08 versus 0.63 ± O.II) was not significant
(p == 0.15).
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nifedipine. The cold pressor test may induce left ventricular
dysfunction (assessed by radionuclide ventriculography) in
at least some patients with coronary artery disease; this has
been reported previously (11-16), and is consistent with
the decrease we observed in our patients. In a recent study
using serial radionuclide ventriculograms (16), 20 normal
subjects responded to the cold pressor stimulus with a small
increase in left ventricular ejection fraction from 0.66 ±
0.08 to 0.69 ± 0.08 (p < 0.01). Twenty additional patients
with coronary artery disease had a decrease in ejection frac-
tion from 0.65 ± 0.06 to 0.59 ± 0.09 (p < 0.001).
Mechanisms of Nifedipine' s Effect
Decreased oxygen demand. Possible mechanisms for
nifedipinc's prevention of a cold pressor-induced decrease
in left ventricular ejection fraction include: 1) decreased
ischemia due to decreased myocardial oxygen demand, 2)
decreased systolic wall stress due to decreased systolic load-
ing of the left ventricle, and 3) decreased ischemia due to
decreased coronary vasoconstriction. In this study, the in-
creases in heart rate and rate-pressure product were com-
parable during the control and nifedipine cold pressor test
(Table 2). Thus, myocardial oxygen demand probably did
not differ (17) during the control and nifedipine cold pressor
tests.
Decreased systolic wall stress. During the control cold
pressor test, both the increase in systolic blood pressure and
the mean peak systolic blood pressure were higher. There-
fore, systolic unloading from nifedipine is likely to account,
in part, for the improvement in the left ventricular ejection
fraction response. The lack of change in relative end-dia-
stolic volume and the blunting of the increase in end-systolic
volume during the cold pressor test after nifedipine suggest
that nifedipine reduced afterload without significantly af-
fecting preload. Previous studies (18,19) have demonstrated
that improvement in left ventricular ejection fraction from
nifedipine was associated with a reduction in left ventricular
afterload.
Decreased coronary vasoconstriction. Finally, nifed-
ipine may exert a beneficial effect on the coronary circu-
lation by inhibiting coronary vasoconstriction. Because of
its calcium-blocking properties (20), nifedipine's vasodi-
lation may be selective for the coronary vasculature. In
animal studies (21,22), norepinephrine-induced contraction
of coronary arteries, unlike systemic arteries, has required
the influx of extracellular calcium. The ability of nifedipine
to block calcium influx could thus inhibit preferentially the
coronary vasoconstrictor response, leaving the systemic
pressor response relatively unaffected. This mechanism may
also help explain the effectiveness of nifedipine in pre-
venting the coronary vasospasm associated with Prinzmet-
al's angina (23), in which altered autonomic nervous system
activity has been postulated as a causative factor in some
patients (24).
Possible Limitations of Study
Certain limitations of the present study should be noted.
First, the study was unblinded to the patients and the phy-
sicians (S.Z.G. and H.D.W.) administering the nifedipine.
Second, the effects of beta-receptor blockade (25) and long-
acting nitrates on the control cold pressor tests could not be
determined. Third, a uniform dosage of nifedipine was ad-
ministered without any attempt to demonstrate a dose-re-
sponse effect. Fourth, absolute radionuclide volumes and
additional systolic ejection indexes were not available to
evaluate left ventricular function more precisely. Despite
these limitations, we believe the most plausible interpre-
tation of these data is that nifedipine exerts a protective
effect on ventricular function during cold pressor exposure
in patients with obstructive coronary artery disease. The
blunting of the decrease in global left ventricular ejection
fraction after the nifedipine cold pressor test may be due,
in part, to improvement in regional performance of myo-
cardium jeopardized by coronary stenoses.
The current study raises the possibility that even in pa-
tients with classic angina, nifedipine may be useful because
of an antivasoconstrictive effect on the coronary vascula-
ture. However, both the lowered systolic blood pressure and
the decrease in baseline left ventricular end-systolic volume
after nifedipine may have reduced left ventricular wall stress
and thereby improved the ejection fraction without selective
coronary vasodilation. Thus, the hypothesis that nifedipine
prevents coronary vasospasm during cold pressor stress in
patients with fixed coronary artery disease could not be
tested directly in this study.
Clinical Implications
Although this study was limited to patients whose left
ventricular ejection fraction at rest was greater than 0.45,
nifedipine may be of particular benefit to patients with more
severe left ventricular dysfunction. In such patients, ex-
posure to cold may precipitate limiting symptoms. Nifedi-
pine has been shown to be well tolerated in such patients
(26) and might be an excellent agent to prevent cold-induced
decreases in left ventricular function.
The results of this study suggest several areas for future
investigation. The cold pressor test could be used to assess
changes in left ventricular function in a comparison study
of nifedipine with drugs that cause afterload reduction with-
out coronary vasodilation (for example, hydralazine) or
coronary vasodilation without afterload reduction (for ex-
ample, dipyridamole). Finally, a study of the nifedipine cold
pressor test that combines simultaneous measurements of
coronary blood flow, coronary sinus metabolites and left
ventricular end-diastolic pressure with radionuclide tech-
niques to evaluate changes in left ventricular volume, car-
diac output and regional myocardial blood flow (27) might
provide additional information to elucidate the mechanisms
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of the protective effect of nifedipine on left ventricular
function.
We thank Beverly H. Lorell, MD, and William Grossman, MD, for their
reviews of this manuscript and Christme Coleman for her assistance in
preparing it.
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